Edgar Lomax Co. VA Sells 34,490 Shares of Pfizer Inc. (NYSE:PFE)

Edgar Lomax Co. VA trimmed its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 2.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,434,310 shares of the biopharmaceutical company's stock after selling 34,490 shares during the period. Pfizer comprises about 2.5% of Edgar Lomax Co. VA's holdings, making the stock its 16th largest position. Edgar Lomax Co. VA's holdings in Pfizer were worth $38,052,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of PFE. Retirement Wealth Solutions LLC bought a new position in shares of Pfizer during the 4th quarter worth $26,000. Rialto Wealth Management LLC bought a new position in shares of Pfizer in the 4th quarter worth $26,000. Kohmann Bosshard Financial Services LLC purchased a new stake in Pfizer during the fourth quarter valued at about $28,000. Noble Wealth Management PBC purchased a new stake in Pfizer in the fourth quarter worth approximately $31,000. Finally, Bernard Wealth Management Corp. purchased a new stake in shares of Pfizer in the 4th quarter valued at $33,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

PFE has been the subject of a number of recent research reports. Cantor Fitzgerald initiated coverage on Pfizer in a research note on Tuesday. They issued a "neutral" rating and a $24.00 target price for the company. UBS Group cut their target price on shares of Pfizer from $28.00 to $24.00 and set a "neutral" rating on the stock in a research note on Tuesday, April 8th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. The Goldman Sachs Group restated a "neutral" rating and issued a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Finally, Guggenheim reiterated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, five have assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $29.57.

Pfizer Stock Performance

PFE traded up $0.50 during midday trading on Tuesday, reaching $22.54. The company had a trading volume of 35,839,138 shares, compared to its average volume of 40,434,188. The company has a market cap of $127.83 billion, a P/E ratio of 15.99, a P/E/G ratio of 0.64 and a beta of 0.67. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54. The business has a 50-day moving average of $24.81 and a two-hundred day moving average of $26.11. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company's revenue for the quarter was up 24.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.10 earnings per share. As a group, equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Insider Activity

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 0.06% of the company's stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.